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Background: Rapid scale-up of antiretroviral therapy (ART) and limited access to genotyping assays in low-resource
settings (LRS) are inevitably accompanied by an increasing risk of HIV drug resistance (HIVDR). The current study
aims to evaluate early warning indicators (EWI) as an efficient strategy to limit the development and spread of
preventable HIVDR in these settings, in order to sustain the performance of national antiretroviral therapy (ART)
rollout programmes.
Methods: Surveys were conducted in 2008, 2009 and 2010 within 10 Cameroonian ART clinics, based on five
HIVDR EWIs: (1) Good prescribing practices; (2) Patient lost to follow-up; (3) Patient retention on first line ART; (4)
On-time drug pick-up; (5) Continuous drug supply. Analysis was performed as per the World Health Organisation
(WHO) protocol.
Results: An overall decreasing performance of the national ART programme was observed from 2008 to 2010: EWI1
(100% to 70%); EWI2 (40% to 20%); EWI3 (70% to 0%); EWI4 (0% throughout); EWI5 (90% to 40%). Thus, prescribing
practices (EWI1) were in conformity with national guidelines, while patient adherence (EWI2, EWI3, and EWI4) and
drug supply (EWI5) were lower overtime; with a heavy workload (median ratio ≈1/64 staff/patients) and community
disengagement observed all over the study sites.
Conclusions: In order to limit risks of HIVDR emergence in poor settings like Cameroon, continuous drug supply,
community empowerment to support adherence, and probably a reduction in workload by task shifting, are the
potential urgent measures to be undertaken. Such evidence-based interventions, rapidly generated and less costly,
would be relevant in limiting the spread of preventable HIVDR and in sustaining the performance of ART
programmes in LRS.
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Low- and middle-income countries had just over 8 million
people receiving highly active antiretroviral therapy
(HAART) by end of 2011, representing 54% [50–60%]
coverage of eligible patients based on World Health
Organisation (WHO) guidelines (CD4≤350 cells/μl) [1].
As compared to 2010 (<6 million) and 2003 (400,000), this
coverage has been greatly favored by the rapid scale-up of
antiretroviral therapy (ART), with sub-Saharan Africa be-
ing the main beneficiary (6.2 million people were receiving
antiretroviral therapy in 2011, up from just 100,000 in
2003) [1,2]. In Cameroon, these efforts led to reductions
in AIDS-associated morbidity and mortality, and a relative
decrease in HIV prevalence (from 5.5% in 2004 to 4.3% in
2011), with close to 44.5% eligible patients on ART [3,4].
Furthermore, the number of ART clinics and of treated
patients has increased overtime: 5 clinics for 116 (1.3%)
eligible patients in 2002, to 145 clinics for 89,455 (36%)
eligible patients in 2010 [4-6]. Since scale-up of ART is
known to be associated with a high risk of HIV drug re-
sistance (HIVDR), strategies to combat HIVDR are of
public health priority in Cameroon [6-8]. Most import-
antly, with limited access to reference laboratory equip-
ment (CD4 count, HIV viral load, HIVDR testing) and the
use of drugs with low genetic barrier for resistance,
HIVDR population-based surveillance and prevention are
recommended to ensure long term efficacy of treatment
guidelines [8-11]. As response to this crucial need, a na-
tional HIVDR working group (HIVDRWG) was created
based on the WHO global HIVDR prevention and assess-
ment strategy which includes the laboratory-based surveys
of transmitted and acquired HIVDR, and monitoring
of HIVDR early warning indicators (EWIs); with the
guidelines being recently revised and updated in 2012
[12-17]. Surveys in Namibia, Malawi, South-Africa, and
other African settings [18-24]; in Central American and
Caribbean countries, as well as in Asia and Oceania
(Papua New Guinea) [23-31], also supported the use of
EWIs to evaluate the risk of ART failure and HIVDR
emergence. Such evaluations use existing clinic- and
pharmacy-based data on ART prescribing at the ART
clinic [12,15,16]. Six strongly recommended and two
optional EWIs are proposed by the WHO, among
which ≥4 feasible EWIs should be chosen for an effective
ART programme evaluation [15]. In this prospect, we
aimed to evaluate the levels and trends of five WHO-
strongly recommended EWIs, in order to identify poten-
tial strengths and weaknesses (i.e. gaps in service delivery
that might inform policy changes to improve perform-
ance) of the national ART program and to target appro-
priate interventions that can optimize care and potentially
minimize the risk of emerging resistant patterns that
could compromise the commonly used antiretrovirals in
the country. Of note, results presented in this study arebased on WHO HIV drug resistance early warning indica-
tor guidance [15], and not upon the updated 2012 guid-
ance as presented in the latest WHO HIV drug resistance
early warning indicator meeting report [16].
Methods
Study design and population
Using a retrospective review of clinical data from ART
sites in Cameroon, five early warning indicators were
assessed in 2008, 2009 and 2010 within 10 Cameroonian
ART clinics. These ART clinics were chosen based on
criteria among which: the number of years of experience
on ART management (≥3 years), the frequency of new
enrollments on ART per quarter (i.e. ≥30 newly enrolled
patients on ART every 3 months), the geographical loca-
tions of the ART clinic over the national territory, and
finally on convenience amongst sites meeting these
criteria. At the beginning of the study in 2008, 133 ART
clinics {24 approved treatment centers [ATCs] and 109
HIV management units: [HMUs]} existed nationwide,
among which 89 were already operational since 2005.
Thus, based on the above mentioned eligibility criteria
(≥3 years experience), our study coverage represented
a proportion of ≈11% (10/89) of the entire national
ART clinics.
The five EWIs were selected and defined according to
the WHO criteria [12,15]:
– EWI1: “Good ARV prescribing practices” (Percentage
of patients initiated on an appropriate first line ARV
drug regimen). Numerator: Number of individuals
initiating ART at the site who are prescribed a
standard or otherwise appropriate first-line regimen
during the selected time period. These are first line
regimens recommended by the country national
guidelines, and exclude dual- or mono-therapy.
Denominator: Number of individuals starting ART
during the selected time period. The acceptable
target performance: 100%.
– EWI2: “Patient lost to follow-up” (Percentage of
patient lost to follow-up after 12 months of
enrolment to ART). Numerator: Number of
individuals initiating ART in a selected time period
that were not seen at the clinic or pharmacy ≥90
days after the date of their last missed appointment
or drug pick-up that occurred within their first 12-
months of ART, and who are not known to have
transferred out or died. Denominator: Number of
individuals starting ART during a selected time
period. The acceptable target performance ≤20%.
– EWI3: “Patient retention on appropriate first line
ART” (Percentage of patient retention on
appropriate first line ART after 12 month of
treatment). Numerator: Number of individuals
Table 1 WHO-sampling method [12,15]
Number of newly enrolled patients


















>10,000 WHO advice required
WHO: World Health Organization.
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time who are, 12 months from ART start, still on
first-line ART (this includes substitutions of one
appropriate first-line regimen for another, but not
substitutions of dual- or mono-therapy or an
inappropriate three-drug regimen). Denominator:
Number of individuals starting ART during a
selected time period or, in sites where data are
available, that number minus the number of
individuals starting ART in that time period who
transferred out during the 12 months after starting
ART. Individuals who died, stopped ART, switched
to second-line ART, or were lost to follow-up must
be included in the denominator. The acceptable
target performance ≥70%.
– EWI4: “On-time ARV drug pick-up” (Percentage of
on-time ARV drug pick-up by the patient).
Numerator: number of individuals who have picked
up all their prescribed ARV drugs on time during
the selected time period. This EWI uses a sample of
all patients on ART, and follows them for two drug
pick-ups after baseline pick-up. Denominator:
number of individuals classified as "on ARV drugs"
during the selected time period. The acceptable
target performance ≥90%.
– EWI5: “Drug supply continuity” (Percentage of ARV
drug supply continuity at the site pharmacy).
Numerator: Number of months or quarters in the
year in which there were no ARV drug stock
outages for any ARVs in any of the standard ART
regimens supplied by the site or the pharmacy at
which the site's patients pick up ARV drugs.
Denominator: 12 months. The acceptable target
performance: 100%.
Sample size for each ART site was calculated based on
the WHO guidance. In detail, for the first year (2008),
considered as the ever first or pilot phase for such study
in the country, a sample size of thirty (30) patients per
site was required. Patient sampling for the two-other
yearly evaluations (2009–2010) was then based on the
total number of new enrollments at ART during the
study year, with respect to the following WHO-
requirements shown in Table 1. This sampling method
derived from the following formula: N = (Z2 x P x Q)/
d2; with N being the minimum sample size, Z the confi-
dence interval at 95% (Z=1.96), P the expected percent-
age of retention on ART, Q as 1- P, and D the precision
at a degree of accuracy (d=7%) [12,15].
Data collection, validation and analysis
Description of each ART site was carried out as per
WHO suggested “site profile”, which includes the cat-
egory of the site (ATC or HMU), the geographicallocalization, years of experience in ART management,
the number of patients on ART, number and category of
trained staff, availability of treatment guidelines, and
availability of first/second line ARV drugs.
Data were collected using WHO data abstraction tools
(standardized sheets) among patients newly enrolled on
ART and followed-up ≥one year. Briefly, the first three
EWIs were obtained by abstraction of cumulative cohort
data from ART registers, while the two other EWIs were
abstracted from the pharmacy register. In order to en-
sure reliability in the quality of data, data verification/
validation was performed using 20% of data from the
medical records. Validation was a two levels process:
firstly on-site (by source verification in ART and phar-
macy registers, against the WHO standardized data col-
lection sheets), and then secondly at the central level (by
verification between the standardized collection sheet
against the WHO-electronic routine data quality assess-
ment tool: “RDQA”). The levels of EWIs were obtained
each year, and the trends were evaluated through, a
chronological analysis, using these 10 ART clinics en-
rolled continuously throughout the three years (2008,
2009 and 2010), and statistically significance overtime
was analyzed for the performance of each EWI using the
Fisher exact test, with a p-value <0.05 considered as a
statistically significant difference. EWI attaining the ac-
ceptable target was classified as “Good Performance”,
while EWI unable to reach the target was classified
as “Poor Performance”.
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With respect to the Helsinki Declaration for research
carried out on humans (including human material or
human data), ethical approval was obtained from the
National Ethics Committee (Authorization N°034/NEC/
SE), Yaounde, Cameroon. Confidentiality was ensured
during data abstraction by the use of identification
codes. Since the study focused on ART site performance
rather than individual patient, informed consent from
patients was not required. For on-site knowledge trans-
fer and owning of EWI activities to staff, heads of the
ART clinics and their respective data managers were
preliminarily trained on HIVDR EWIs and on the meth-
odology for data collection, analysis and interpretation.
Results
Description of the ART clinics
Data validation was successful for all the 10 ART clinics
throughout the three years (2008, 2009 and 2010). These
ART clinics were geographically distributed in four differ-
ent regions of the country, among which four sites from
the Centre region (Yaounde General Hospital, National
Social Welfare Hospital, Yaounde Central Hospital, and
Yaounde Jamot Hospital); three sites from the Littoral
region (Douala General Hospital, Laquintinie Hospital
Douala, and Nylon District Hospital); two sites from
the North-west region (Bamenda Regional Hospital,
and Polyclinic Mezam Bamenda); one site from the
South-west region (Limbe Regional Hospital).
These ART clinics had a median working experience
in the HIV/AIDS therapeutic management of 6.5 years
[Interquartile range, IQR: 5–7]. The national ART guide-
lines were available in all the sites, as well as treatment
protocols for first line ARV drugs; second line drug regi-
mens were available solely in ATCs. ARV drugs were
provided at a pharmacy within the clinic; and drug
stocks were run using designed sheets.
Throughout the study, each of the clinics had more
than 30 patients newly enrolled on ART quarterly (i.e. in
every three months period). By the end point (i.e. in
2010), a total 27,826 patients were on ART in the entire
study clinics, and staffs (physicians, nurses, pharmacists/
clerks, biologists/laboratory technicians, counselors, data
managers, community relay agents) were all trained on
the routine management of people living with HIV. The
staff-patient distribution per site was as follows: Yaounde
General Hospital (1,542 patients for 24 staffs; ≈64/1
ratio), National Social Welfare Hospital (1,247 patients
for 178 staffs; ≈6/1 ratio), Yaounde Central Hospital
(6,031 patients for 43 staffs; ≈140/1 ratio), and Yaounde
Jamot Hospital (1,610 patients for 33 staffs; ≈49/1 ratio),
Douala General Hospital (2,049 patients for 34 staffs;
≈61/1 ratio), Laquintinie Hospital Douala (3,831 pa-
tients, staffs number not provided), Nylon DistrictHospital (2,800 for 34 staffs; ≈83/1 ratio), Bamenda
Regional Hospital (4,032 patients for 31 staffs; ≈130/1
ratio), Polyclinic Mezam Bamenda (2,100 patients for 18
staffs; ≈117/1 ratio), and Limbe Regional Hospital (2584
patients for 191 staffs; ≈14/1 ratio). Thus, this resulted
to an overall median staff-patient ratio of ≈1/64 [Inter-
quartile range (IQR): 1/49 – 1/117], indicative of a heavy
workload; interestingly, the only ART site with ≥50%
good performance over the three years survey (H. CNPS:
60% good performance i.e. 9/15, as shown in Table 1)
had the lowest workload (1/6 staff/patient ratio). An
overview distribution of patients per staff category was
as follows: medical doctor (1:267 patients); nurse (1:74
patients); biologists/laboratory technicians (1:434 pa-
tients); pharmacist/pharmacy clerk (1:694 patients);
counselor (1:434 patients); community relay agent (1:323
patients); and data manager (1:1387 patients).
Performances of EWIs in 2008, 2009, and 2010
For EWI1, the overall yearly performance moved from
100% (10/10) in 2008, 80% (8/10) in 2009, to 70% (7/10)
in 2010; without any statistically difference overtime (p=
0.47). Of note, the few sites with suboptimal perfor-
mances had each a target of 98-99%, which is much
closed to the required performance of 100%. No dual- or
mono-therapy was reported in any of the studied clinics.
For EWI2, only 40% (4/10) reached the required target
(≤20%) in 2008 against 20% (2/10) in 2009 and 20% (2/10)
in 2010; revealing an increasing rate of patients lost to
follow-up between the first two years, followed by stable
rate; still without any statistically significant difference
over time (p=0.82).
For EWI3, 70% (7/10) of sites reached the required
performance target (≥70%) in 2008, against 10% (1/10)
and 0% (0/10) in 2009 and 2010, respectively; describing
an overall decreasing performance in terms of patient re-
tention on first line ART, with a statistically significant
difference overtime (p= 0.0049).
For EWI4, the rates of patients with on-time drug pick-
up were extremely below the required target (≥90%)
during each of the three years. In details, the median per-
formances varied from 36.5% [IQR: 28-47%] in 2008, to
15% [IQR: 10-21%] in 2009, and to 33% [IQR: 21-37%] in
2010; with a statistically significant difference overtime
(p= 0.0132).
For EWI5, drug availability, also known as continuity
in drug supply, decreased significantly (p= 0.006) from
90% (9/10) in 2008 to 20% (2/10) in 2009, then later
reported a non-significant increment (p=0.625) to 40%
(4/10) in 2010. Interestingly, throughout the three years,
the overall performance showed a significant drop down
in drug supply overtime (p=0.023).
The overall trends (from 2008–2010) of the five
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Figure 1 Trends of EWIs from 2008–2010. EWI1: Early Warning Indicator 1, EWI2: Early Warning Indicator 2, EWI3: Early Warning Indicator 3, EWI4: Early
Warning Indicator 4, EWI5: Early Warning Indicator 5. For each EWI, the graphs represent the national performance in 2008, 2009, and 2010, respectively.
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mances on prescribing practices (EWI1) without any sta-
tistically significance, while the other four EWIs revealed
suboptimal and decreasing performances overtime, most
often (3/4) with significant differences overtime. The de-
tail performance of EWIs, during each of the three years,
and in each of the 10 surveyed ART clinics, is reported
in Table 2.
Discussions
The increasing need to control HIVDR in low-resource
settings (LRS) requires the implementation of efficient
and rapid approaches to limit the emergence of prevent-
able HIVDR, among which a population-based survey,
such as EWI evaluations, could yield relevant evidences
based-recommendations for best clinical practices. Over-
all, this is a paper on a topic of high importance in HIV
medicine, transmitted drug resistance, as well as the
methods for detecting it in a LRS where genotyping is
not available, and remains challenging and clinically im-
portant issues to all the stakeholders who are involved in
the global scale up of ART, particularly in Africa.
Physicians’ prescribing practices (EWI1) remained na-
tionwide in conformity with the national guidelines. Inter-
estingly, even sites with the 98-99% performances for
EWI1 had no cases of dual- or mono-ARV prescriptions,
which are more likely to select for drug resistant HIV ra-
ther than an inappropriate prescribing of drugs such as
boosted protease inhibitors, abacavir, or tenofovir (which
may not be appearing on several guidelines) which likelyhave less significance related to HIVDR. This good prac-
tice was mainly due to the use of standardized ART regi-
mens and the institution of a consortium agreement
(therapeutic committee) for every treatment initiation.
This is a weekly consortium body made up of health staff
all trained in HIV/AIDS management (medical doctors,
nurses, medical biologists/laboratory technicians, medical
counselors, pharmacists/pharmacy clerks, data manager
and/or community relay agents; a practice which merits
to be encouraged. Globally, 75% of clinics monitored
worldwide met the WHO-recommended target on pre-
scribing practices [16]. Specifically, other African coun-
tries (Malawi, Namibia, and others) also reported good
practices [18-24], while poor performances were observed
out of Africa (Central American, Caribbean, Asian,
Oceanic and Western Pacific: from 38 to 75%) [23-31].
Lack of evaluation overtime in the above mentioned stud-
ies could not enable in-depth comparison to ours. Still,
the use of a therapeutic committee as well as continuous
training may be vital practices to maintain and/or improve
good ARV prescriptions.
The high and increasing rates of lost-to-follow-up are
indicative of a growing rate of patients harboring poten-
tial drug resistant viruses within the national context,
which in turns supports a growing risk of HIVDR emer-
gence in Cameroon. These would have been favored by
the observed heavy workload, and also probably due to
termination of working contracts for community relay
agents (CRA). Thus, task shifting (from medical doctors
to nurses), and probably community empowerment (by














per site % (n/total)
2008 2009 2010 2008 2009 2010 2008 2009 2010 2008 2009 2010 2008 2009 2010
Y.G.H 100% 100% 100% 37% 39% 35% 63% 47% 56% 47% 19% 29% 92% 33% 58% 20% (3/15)
(30/30) (200/200) (135/135) (11/30) (77/198) (47/135) (19/30) (94/200) (76/135) (14/30) (37/192) (39/135) (11/12) (4/12) (7/12)
H. CNPS 100% 100% 99% 10% 20% 20% 90% 70% 56% 30% 39% 37% 100% 50% 100% 60% (9/15)
(30/30) (200/200) (158/160) (3/30) (39/194) (20/132) (27/30) (133/193) (90/160) (9/30) (78/200) (58/157) (12/12) (6/12) (12/12)
Y.C.H 100% 100% 100% 27% 31% 39% 77% 38% 55% 28% 12% 32% 100% 92% 67% 33% (5/15)
(30/30) (200/200) (180/180) (8/30) (62/200) (64/165) (23/30) (76/200) (94/170) (8/30) (24/200) (58/180) (12/12) (11/12) (8/12)
Y.J.H 100% 100% 100% 10% 46% 43% 77% 27% 50% 3% 15% 56% 100% 75% 75% 40% (6/15)
(30/30) (200/200) (155/155) (3/30) (86/186) (60/139) (23/30) (51/186) (73/145) (1/30) (29/196) (86/153) (12/12) (9/12) (9/12)
D.G.H 100% 100% 99% 40% 41% 38% 60% 47% 36% 50% 57% 50% 100% 25% 100% 27% (4/15)
(30/30) (188/188) (158/160) (12/30) (76/185) (60/160) (18/30) (89/188) (58/159) (15/30) (113/199) (74/147) (12/12) (3/12) (12/12)
L.H.D 100% 100% 99% 37% 29% 33% 63% 66% 60% 43% 21% 34% 100% 100% 100% 33% (5/15)
(30/30) (200/200) (158/160) (11/30) (58/200) (53/160) (19/30) (132/200) (93/156) (13/30) (41/194) (54/160) (12/12) (12/12) (12/12)
N.D.H 100% 100% 100% 33% 15% 58% 70% 35% 44% 30% 10% 12% 100% 50% 100% 47% (7/15)
(30/30) (200/200) (175/175) (10/30) (25/162) (101/175) (21/30) (127/194) (70/159) (9/30) (19/200) (20/171) (12/12) (6/12) (12/12)
L.R.H 100% 99% 100% 27% 40% 19% 73% 57% 44% 13% 2% 0% 100% 100% 42% 40% (6/15)
(30/30) (196/198) (160/160) (8/30) (80/200) (30/160) (22/30) (113/199) (68/153) (4/30) (3/199) (0/160) (12/12) (12/12) (5/12)
B.R.H 100% 100% 100% 20% 97% 41% 70% 1% 49% 43% 15% 34% 100% 50% 17% 40% (6/15)
(30/30) (200/200) (172/172) (6/30) (193/198) (68/167) (21/30) (2/200) (82/167) (13/30) (29/197) (50/146) (12/12) (6/12) (2/12)
P.M.B 100% 98% 100% 10% 32% 25% 87% 34% 53% 77% 9% 21% 100% 42% 42% 33% (5/15)
(30/30) (176/180) (114/114) (3/30) (54/170) (28/114) (26/30) (60/180) (62/117) (23/30) (19/211) (26/125) (12/12) (5/12) (5/12)
Legend Table 1: in “Bold” are performances that meet the required target.
Y.G.H: Yaounde General Hospital; H. CNPS: National Social Welfare Hospital; Y.C.H: Yaounde Central Hospital; Y.J.H: Yaounde Jamot Hospital; D.G.H: Douala General Hospital; L.H.D: Laquintinie Hospital Douala; N.D.H:
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tions and reduced laboratory costs in such poor settings,
may help in reducing the rate of missing patients. In-
deed, the numbers of required health care workers to
provide ART in LRS (1–2 physicians/1000 patients, 2–7
nurses/1000 patients, <1-3 pharmacy staff/1000 patients,
and wider ranges for other health-allied staffs) estimated
by Hirschhorn et al. [32], was based on the WHO-3by5
target (i.e. treatment of 5 million patients by 2005), and
currently need to be revised in order to match the grow-
ing ART coverage (presently >8 millions) [1]. With re-
striction to the WHO-protocol, a direct evidence-based
evaluation has not yet been conducted to investigate on
the real impact of CRA’s disengagement on lost to
follow-up. Globally, 69% of clinics monitored worldwide
met the WHO-recommended target [16]. Particularly, in
other African countries, lost-to-follow-up is also challen-
ging (40 to 75%) [18-24], whereas out of Africa higher
performances were recorded (54 to 100%) [23-31]. Fur-
thermore, the impact of distance to the clinic, waiting
time prior to medical consultation, stigma and patient
educational level, are factors that may help in reducing
lost patients [33]. Indeed, ART uptake has been nega-
tively associated with distance from the nearest primary
healthcare [34,35], thus indicating a possible need for
creating new ART clinics to foster adherence.
The gradual poor retention of patients on first line
ART after 12 months ART may be indicating a rapid
switch to second line regimens that could be explained
by numerous other factors (wider availability of HIV
Viral Load testing, greater clinician experience/aware-
ness on identifying treatment failure, a preexisting drug
resistant mutation, etc.). Further studies are therefore
needed to determine the time-to-treatment, to imple-
ment measures toward long term efficacy of first line
ART and to limit events of inappropriate switch to sec-
ond line ART in these settings. Furthermore, failure to
be on first line therapy one year after initiation might in
fact not necessarily be a negative indicator, since it might
indicate a correct and necessary treatment switch to sec-
ond line. This observation makes questionable the over-
all utility of EWI3, which would likely need to be revised
for better utility in future. Globally, 67% of clinics moni-
tored worldwide met the WHO-recommended target
[16]. More interestingly, our performances in 2008 (70%)
were similar to those found in other African settings
(among which Malawi: 53% and Namibia: 67%) [18-24],
while higher performances (62-90%) were recorded out
of Africa [23-31]. Since first line ARV drugs (≈$100/
patient/year) are about 4 times less costly than second
line, an effective retention on first line is economical
[36] and may regulate the current fast switch to second
line ARV (2% of total patients on ART in 2006, to 13% of
total patients on ART in 2009) in Cameroon [4]. Theseanalyses are consistent with the different HIVDR rates to
NRTI and NNRTI in 2003 (before ART scale-up: 5.6%
M184V and 6.1%Y181C) and thereafter (following ART
scale-up: 16.3%M184V and 63.7%Y181C) [37]. Despite
the higher rate of transmitted HIVDR in Latin America
(12-20%), sub-Saharan Africa, though with only 4-9% of
transmitted HIVDR, is experiencing a rapid scale-up of
ART associated with an increasing rate of transmitted
HIVDR (38% increasing risk of HIVDR per year): this im-
portant fact urgently needs a regular HIVDR surveillance
system [14,16,38].
The overall delay in drug pick-up strongly supports a na-
tional revision of the community engagement strategy to
support patient adherence to ART programmes. This poor/
decreasing performance in drug pick-up (EWI4), together
with EWI2 and 3, clearly placed patient non-adherence as
the main factor with high risks of HIVDR development and
spread within the community. However, it should be noted
that EWI4 itself seems problematic and may not be entirely
practical to address adherence issues. Indeed, in our setting,
clients may present one-to-two day(s) after their required
drug pick-up appointment date and still maintain 100%
ART adherent, due to availability of remaining pills from
the previous appointment. Thus, as for EWI3, the overall
utility of EWI4 may also be brought into question, and
would likely require expert review or reconsideration. Thus,
the low scores found in our study are partly explained by
the rigidity of this indicator, which has further being
recently modified in the 2012 HIVDR report [16]. Globally,
70% of clinics monitored worldwide met the WHO-
recommended target for timely drug keep-up [16]. Detail
analysis also reports lower timely drug pick-ups in
other African settings (between 17% and 41%) [18-24],
against settings out of Africa (73-100%) [23-31]. Thus, in
African AIDS programmes, issues such as “time spent by
patient for pharmacy service”, “service quality rendered by
pharmacy staff”, “pharmacy localization”, may be partly
explained by delays in drug pick-up. As suggested by
El-Khatib et al. in 2011, adherence to drug-refill (pill count)
may also be a useful EWI of virologic and immunologic
failure on first-line ART in African settings [23].
The gradual poor performances in drug supply present
EWI5 as the main programmatic setback in the national
ART performance. Despite the provision of alternative
ART (by replacing shortage of efavirenz with nevirapine
or lopinavir/ritonavir) in case of drug discontinuity,
stock outs still negatively impact patient adherence with
non-negligible risks of HIVDR due to potential subopti-
mal drug levels. Drug supply machinery should be ur-
gently revised. Our findings could be strengthened by
conducting further investigations to as to why these stock
outs are occurring; targeting specifically the supply lines,
trade agreements specific to Cameroon, land versus air
versus sea route issues, or in-country distribution network
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met the WHO-recommended target for drug supply. Geo-
graphically, the procurement systems were successful
(100%) in Malawi (cross-sectional study) [18], and with an
increasing performance in the Caribbean (31.3%-94%,
from 2007–2009) [23,24]. Aggregated data showed poorer
performance in sub-Saharan Africa (42%-47%), as com-
pared to non-African countries (32-90%) [20-31]. Thus,
African settings are more in need of further investigations
to improve their drug supply system.
Lessons learnt from the three year survey
This study has effectively identified some strengths and
weakness of the national ART programme, amongst which
the encouraging prescribing practices, and corrective mea-
sures been addressed for other EWIs. Indeed, the per-
formance of these later EWIs has decreased over time
rather than staying steady or improving (as would have
been hoped). Thus, this result is also very interesting, and
if taken at face value, is a serious indictment of the overall
implementation strategies underway in Cameroon, and a
crucial cause for concern for generation of drug resistance.
Therefore, tasks shifting/decentralization (to alleviate the
heavy workload) and community re-empowerment are
underway [4,39]. A specific algorithm (in form of posters
and hand-outs) presenting overall performances and ad-
dressing adapted corrective actions, has been provided to
guide healthcare providers working at the ART clinic (see
Additional file 1). Also, advocacy, addressed to health au-
thorities (ministry and heads of health facilities), boosted
the implementation of the above corrective measures.
Additionally, a bottom-to-top approach, through consid-
eration of associations of people living with HIV, would
allow patients to participate as key players in the success
of the national ART performance [33,35,36,39]. Site super-
vision is also essential for an effective integration of
HIVDR activities in the routine clinical practices, to make
EWI an instrumental in prioritizing measures and allocat-
ing resources for clinics. Our analyses suggest that ART
programmes in other LRS may be experiencing similar
declining performances, and thus need relevant measures.
Challenges resulting from our findings
A successful and sustainable ART programme performance
should be accompanied by scalable EWI survey in the
country; the major setback relies on the regular availability
of the required resources [12]. Secondly, despite the avail-
ability of external support, additional fund raising is still
needed to optimize patient healthcare. Continuous staff
training is essential to sustain good practices; brain drain
makes the heavy workload persistent, thereby calling for
policies to train and retain qualified personnel, especially
with the need/creation of new ARTclinics in the country to
ensure scaling-up of the treatment programmes [36]. Moreimportantly, recent studies in Cameroon showed low to
moderate levels of transmitted HIVDR [40], and increasing
levels of acquired HIVDR after 12 and 24 months [41], thus
predicting growing risks of treatment failure and HIVDR to
the commonly used drugs, due to a broad range of factors
[35,39]. Without attempting to create a direct temporal re-
lationship, the increasing rate of transmitted and acquired
HIVDR in Cameroon, alongside the increasing/widely avail-
ability of ARV treatment, supports also a growing need of
affordable viral load and HIVDR testing, and a more regu-
lar surveillance of HIVDR in this country [8,38]. Pediatric
HIVDR surveillance is of prime importance, and needs to
be implemented [42]. Of note, as observed in other coun-
tries, Fokam et al. also found low (4.9%) and high (90%)
rates of HIVDR among drug-naïve and first-line ART fail-
ing children in Cameroon, respectively [43]. Finally, the
emerging HIV co-infections with tuberculosis, malaria, viral
hepatitis, require setting-up an antimicrobial drug resist-
ance strategic plan and working group to preserve active
drugs for the next generation [44,45].
Despite restrictions to WHO-standards, our study lim-
itations could not allow greater/meaningful statistical
analysis, due to the limited number of sampled ART
sites. Furthermore, difficulties in evaluating other factors
that could potentially affect ART performances (disen-
gagement of CRAs, task shifting, distance to clinic,
stigma/discrimination, educational level, bottle nets in
the drug supply system, etc.) also limited the strengths
of our recommendations.
Conclusions
The extended use of ART in developing countries war-
rants a thorough understanding of all factors contribut-
ing to the success of national ART programmes. In the
Cameroonian setting, patient adherence, drug stock
outs, a potential community disengagement and a prob-
able heavy workload, appear as major factors favoring an
increasing risk of HIVDR emergence.
Use of EWI is an effective approach to identify both
patient and programmatic factors favoring the risks of
HIVDR at the clinics and at the national levels. With its
simplicity, low cost, and rapid evidence-based policy-
making, such surveys would be useful for a successful
scale-up of ART in LRS, which in turns contribute to
the global HIVDR prevention and surveillance strategy.
Additional file
Additional file 1: Recommendations to limit HIV Drug Resistance in
Cameroon.
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